X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
adult (8) 8
female (7) 7
index medicus (7) 7
male (7) 7
middle aged (7) 7
aged (6) 6
hematology (4) 4
aged, 80 and over (3) 3
antibodies, bispecific - adverse effects (3) 3
antibodies, bispecific - therapeutic use (3) 3
cancer (3) 3
oncology (3) 3
t-lymphocytes - immunology (3) 3
therapy (3) 3
abridged index medicus (2) 2
antibodies, bispecific - administration & dosage (2) 2
antibodies, bispecific - pharmacokinetics (2) 2
antigens, cd19 - immunology (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
b-lymphocytes - immunology (2) 2
care and treatment (2) 2
cd3 complex - immunology (2) 2
chemotherapy (2) 2
construct (2) 2
cytotoxicity (2) 2
disease-free survival (2) 2
flow cytometry (2) 2
immunotherapy (2) 2
immunotherapy - methods (2) 2
lymphomas (2) 2
minimal residual disease (2) 2
potent (2) 2
precursor b-cell lymphoblastic leukemia-lymphoma - therapy (2) 2
single-chain antibody (2) 2
t-lymphocytes - drug effects (2) 2
t-lymphocytes, cytotoxic - immunology (2) 2
treatment outcome (2) 2
trials (2) 2
young adult (2) 2
2nd-line treatment (1) 1
5-fluorouracil (1) 1
activation (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - pathology (1) 1
adolescent (1) 1
adult patients (1) 1
agammaglobulinemia - chemically induced (1) 1
age (1) 1
anemia (1) 1
antibodies (1) 1
antibodies, bispecific - immunology (1) 1
antibody blinatumomab (1) 1
antibody specificity (1) 1
antigens, cd19 - metabolism (1) 1
antigens, neoplasm - immunology (1) 1
antilymphocyte serum - administration & dosage (1) 1
antilymphocyte serum - adverse effects (1) 1
antilymphocyte serum - metabolism (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - pharmacology (1) 1
b lymphocytes (1) 1
b-cell lymphoma (1) 1
b-lineage (1) 1
b-lymphocytes - pathology (1) 1
bacteria (1) 1
benzoates - administration & dosage (1) 1
benzoates - adverse effects (1) 1
benzoates - therapeutic use (1) 1
bevacizumab (1) 1
bispecific antibody (1) 1
blood (1) 1
blotting, western (1) 1
bone marrow (1) 1
bone marrow - pathology (1) 1
bone-marrow-transplantation (1) 1
camptothecin - administration & dosage (1) 1
camptothecin - analogs & derivatives (1) 1
carcinoma, renal cell - drug therapy (1) 1
carcinoma, renal cell - immunology (1) 1
cell lineage (1) 1
cell membrane - metabolism (1) 1
cell separation (1) 1
cellular biology (1) 1
chelating agents (1) 1
child (1) 1
children's hospitals (1) 1
chronic myelogenous leukemia (1) 1
chronic-phase (1) 1
clarithromycin - administration & dosage (1) 1
clinical-significance (1) 1
clinical-trials (1) 1
cml (1) 1
cohort studies (1) 1
colonic neoplasms - drug therapy (1) 1
colonic neoplasms - pathology (1) 1
combination (1) 1
combined modality therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 18, pp. 2493 - 2498
Journal Article
Science, ISSN 0036-8075, 8/2008, Volume 321, Issue 5891, pp. 974 - 977
Journal Article
Blood, ISSN 0006-4971, 06/2012, Volume 119, Issue 26, pp. 6226 - 6233
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 1589 - 1589
Abstract Introduction: Blinatumomab (blin), a CD19/CD3 bispecific T-cell engager (BiTE®) antibody construct, has shown clinical efficacy in patients with both... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 4460 - 4460
Abstract Introduction: Treatment of relapsed or refractory DLBCL can be challenging and little progress has been made in recent years. Blinatumomab, a... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 1811 - 1811
Abstract Introduction Blinatumomab, a bispecific T-cell engager (BiTE®) that redirects cytotoxic T cells to CD19+ B-lineage cells, has shown anticancer... 
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2010, Volume 47, Issue 2, pp. 206 - 214
Journal Article
European Journal of Haematology, ISSN 0902-4441, 03/2012, Volume 88, Issue 3, pp. 260 - 268
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 21, pp. 3965 - 3965
Abstract Abstract 3965 INTRODUCTION: So far, monoclonal antibodies have not yielded convincing therapeutic success in multiple myeloma (MM). Therefore, the... 
Journal Article
Blood, ISSN 0006-4971, 11/2009, Volume 114, Issue 22, pp. 4793 - 4793
Abstract Abstract 4793 Blinatumomab is a CD19/CD3-bispecific antibody construct of the bispecific T cell engager (BiTE®) class showing as single agent a high... 
Journal Article
Blood, ISSN 0006-4971, 11/2009, Volume 114, Issue 22, pp. 3805 - 3805
Abstract Abstract 3805 Poster Board III-741 Background Red blood cell (RBC) transfusions on a regular basis are unavoidable in a variety of chronic anemias.... 
Journal Article
Blood, ISSN 0006-4971, 11/2009, Volume 114, Issue 22, pp. 2723 - 2723
Abstract Abstract 2723 Poster Board II-699 Indolent and mantle cell lymphoma (MCL) are predominantly treated with chemotherapy or a combination of chemotherapy... 
Journal Article
Blood, ISSN 0006-4971, 11/2009, Volume 114, Issue 22, pp. 4798 - 4798
Abstract Abstract 4798 Blinatumomab is a single-chain bispecific antibody construct with specificity for CD19 and CD3 belonging to the class of bispecific T... 
Journal Article
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 21, pp. 2880 - 2880
Abstract Abstract 2880 Blinatumomab (MT103) is a single-chain bispecific antibody construct with specificity for CD19 and CD3 belonging to the class of... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.